Last reviewed · How we verify
Hematological indicators
At a glance
| Generic name | Hematological indicators |
|---|---|
| Sponsor | Ya-Wei Xu |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Cardiac Magnetic Resonance for Diagnosis, Treatment Guidance and Prognosis of Cardiac Masses (CMR)
- Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases (PHASE2, PHASE3)
- The Effect of a Training Programme in the Variation of Fitness Parameters, Physiological, Hematological and Biochemical Indicators of Soccer Players During the Preseason Period
- Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA/TD-NSAA (PHASE3)
- Body Composition and Nutritional Status in Pediatric Patients With Hematological Malignancies (NA)
- Identification and Functional Study of Novel Biomarkers for Cardiovascular Diseases
- Risk Factors of Postoperative Complications and Survival Rate in Pancreatic Ductal Adenocarcinoma Patients
- The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hematological indicators CI brief — competitive landscape report
- Hematological indicators updates RSS · CI watch RSS
- Ya-Wei Xu portfolio CI